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Abstract-The need for self-protecting polymer or alloy implants resistant to a broad spectrum of bacterial challenges led us to investigate
covalent bonding of minocycline (MIN), a tetracycline derivative, to polystyrene beads and to titanium alloy foils by oligoethylene glycol
spacers. 9-Hydrazino-acetyl-amido-MIN, and simpler glycylcycline derivatives, retained minimum inhibitory concentration (MIC)
against Staphylococcus aureus comparable to MIN. However, PEG-glycyl-amido-MIN showed very low activity. Hence, we coupled 9hydrazino-acetyl-amido-MIN to the aldehyde termini of oligoethylene glycol spacers bonded to polystyrene and titanium alloy surfaces to
form acid-releasable hydrazone linkages. 9-Hydrazino-acetyl-amido-MIN was released from the monolayers more rapidly at pH 5.0 than
at pH 7.4. ©2007 Elsevier Science Ltd. All rights reserved.

Infections are a devastating complication of medical
implant devices that cause significant morbidity. The
management of infected implants has serious economic
implications. For example, in the United States,
treatment of 3500-4000 cases of knee and hip infections
every year costs an estimated 150 to 200 million
dollars1. Because of poor vascularity and biofilm
formation at the implant sites, such infections have
proven difficult to prevent or treat. The local application
of antibiotics is a well-known and accepted therapy for
such kind of implications2-4. Current practice includes
antibiotic-impregnated bone cement5, and antibioticcontaining coating systems6-8. These methods are
intended to release antibiotics rapidly and irreversibly,
and require a carrier material other than the orthopaedic
implant itself to transport the antibiotic materials. Some
non-resorbable materials used in the methods even need
to be removed after the surgery9.

The strategy was then extended to Ti6Al4V alloy pins,
widely used for orthopaedic implants16. We found that
VAN could be covalently linked to the Ti6Al4V alloy
surface on orthopaedic implants, following oxidation17.
Covalently bound VAN was retained on the surface for
an extended period of time and retained significant
antibiotic activity18.

Because of the combination of their many
biocompatible properties, titanium and titanium alloys
are frequently applied in a wide variety of biomedical
devices10. In our initial studies11 using fine titanium (Ti)
particles which had been aminopropylated12,13, we
utilized the last resort glycopeptide antibiotic
vancomycin (VAN), which acts at the surface of the
Gram-positive bacterial cell wall to block peptidoglycan
synthesis14,15. Hydrophilic bis(ethylene glycol) spacers
were coupled to the solid phase NH2PrSiO-Ti particles,
followed by VAN11. The biological results showed that
the VAN-modified Ti particles effectively inhibited the
growth of S. aureus compared with control Ti particles
on which the bacteria grew abundantly11.

Glyclcyclines, such as tigecycline, recently approved by
FDA20, are active against a broad range of Grampositive and Gram-negative bacterial strains resistant to
tetracycline or doxycycline. Tigecycline, however, lacks
functional groups suitable for connecting to a solid
support. Minocycline (MIN), on the other hand, allows
exclusive 9-nitration, the starting point for glycylcycline
extension.
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Most implant infections are caused by Gram-positive
bacteria19, but some are caused by Gram-negative
bacteria, which are susceptible to broad-spectrum
antibacterial agents such as tetracyclines. Bacterial
resistance to tetracyclines has curtailed their clinical
effectiveness. A minimum of semisynthesis and
analoging has been carried out with tetracyclines,
compared to other classes of antibiotics, perhaps due to
their complex chemistry, chemical liability, and lack of
reactivity of the intact naphthacene nucleus.

MIN is effective against a broad range of Gram-positive
and Gram-negative bacteria21, displaying an MIC of
0.12 µg/mL against S. aureus22. Against E. faecalis and
E. faecium, by comparison, MIN was found ~8-fold
more active than linezolid and 32-fold more than
quinupristin-dalfopristin23. Bulky groups at the 9position of glycylcyclines usually contribute to
activity24, supporting our strategy of coupling moieties
to the 9-position of MIN to create new glycylcyclines.
We therefore chose MIN as the basis for glycylcycline
tethering to solid surfaces.

Here we report the design and synthesis of several MIN
C9 derivatives and the determination of their minimum
inhibitory concentration (MIC). Attachment of the MIN
derivatives to polystyrene beads and Ti6Al4V alloy
foils via acid-labile linkers was carried out to
characterize the bioactivity of the tethered MIN
derivatives.
We synthesized [4S-(4α,12aα)]-9-H2N-4,7-bis(Me2N)1,4,4a,5,5a,6,11,12a-octohydro-3,10,12,12a–
tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide (9H2N-MIN) as described22. Briefly, to an ice-cold
solution of MIN·HCl (1 gram, 2.03 mmol) in 9 mL of
concentrated H2SO4 was added KNO3 (224 mg, 2.4
mmol). The reaction mixture was stirred at 0˚C for
about 1.5 hour, and monitored by HPLC on a 150×4.6
mm Phenomenex® Luna phenyl-hexyl 5 µm column,
eluted with 25% CH3CN in 35 mM Na2HPO4, pH 7.5,
on a Waters 600 liquid chromatograph (Milford MA
USA). When the reaction came to completion, the
mixture was slowly poured into 240 mL of ice-cold
Et2O. The precipitate was collected by filtration, and
washed with Et2O three times. The solid was dried
overnight under vacuum to give 9-O2N-MIN·(SO4)2.
The product was characterized by HPLC, showing a
prominent product peak, and MS of the main peak
(SELDI-TOF mass spectrometer (Ciphergen, Fremont,
CA), calc. 502.47 Da, found 502.5 Da. The dried 9O2N-MIN·(SO4)2 (1.29 g, 1.8 mmol), 200 mg of 10%
palladium on charcoal, and 4.5 mL of 2 N H2SO4 in 6
mL of 2-MeOEtOH were mixed and hydrogenated in a
Parr apparatus at 40 psi for 1.5 hr. The catalyst was
filtered and the filtrate was added dropwise to a mixture
of 2-PrOH (210 mL) and Et2O (150 mL). The yellow
solid was collected by filtration, washed several times
with Et2O and dried under vacuum at room temperature
overnight to yield 1.16 g of 9-H2N-MIN·(SO4)2 (90%
yield). The product was characterized by HPLC and
MS: calc. 472.2 Da, found 472.0 Da.

Next, we prepared [4S-(4α, 12aα)]-4, 7-Bis(Me2N)-9[(HNAc)NH]-4,7-bis(Me2N)-1,4,4a,5,5a,6,11,12aoctohydro-3,10,12,12a–tetrahydroxy-1,11-dioxo-2naphthacenecarboxamide (9-hydrazino-Ac-H2N-MIN)
(Scheme 1). To a solution of N,N,N’-Boc3hydrazinoacetic acid (369 mg, 0.95 mmol) in 3 mL
Me2NCHO was added 397 mg of HATU (1.1
equivalent) and 264 µl of iPr2EtN. The reaction mixture
was stirred at room temperature for 30 min, then mixed
with 9-H2N-MIN·(SO4)2 (600 mg, 0.9 mmol) in 4 mL
Me2NCHO and 1 g of NaCO3, and stirred for 1 hr at
room temperature. It was found that the yellow solution
changed to brown. The solid was removed by filtration
and the filtrate was applied to a 150×15 mm C18 column
(WAT 020594, Waters Associates). The column was
washed with H2O to remove Me2NCHO. Because of the
strong hydrophobicity of 9-Boc3-hydrazino-Ac-NHMIN, the impurities in the reaction mixture could be
eluted from the C18 column by 20% CH3CN in aqueous
0.1% CF3CO2H. The product was eluted with pure
CH3CN, concentrated by rotatory evaporation, and
lyophilized overnight. The dried sample was dissolved
in 4 M HCl in dioxane to deprotect the Boc groups.
After 10 min, a precipitate was formed. The mixture
was kept at room temperature under shaking. The
precipitate was collected by filtration and washed with
Et2O three times. The solid product was dried under
vacuum to give 510 mg of 9-hydrazino-Ac-H2N-MIN
·(Cl)2 as a yellow powder (92% yield). The product was
characterized by HPLC and MS: calc. 544.56 Da, found
544.6 Da.
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We then converted 9-H2N-MIN into [4S-(4α,12aα)]-9[(HNAc)NH]-4,7-bis(Me2N)-1,4,4a,5,5a,6,11,12aoctohydro-3,10,12,12a–tetrahydroxy-1,11-dioxo-2naphthacenecarboxamide (9-Gly-NH-MIN). To a
solution of Boc-Gly (458 mg, 1.2 mmol) in 3 mL
Me2NCHO was added 412 mg of 2-(7-aza-1Hbenzotriazole-1-yl)-1,1,3,3-tetramethyl-uronium hexafluorophosphate (HATU) (Applied Biosystems, Foster
City CA, USA) (1.1 equivalent) and 311 µL of iPr2EtN.
The reaction mixture was stirred at room temperature
for 30 min, then mixed with 9-H2N-MIN·(SO4)2 (575
mg, 0.95 mmol) in 4 mL Me2NCHO. After 1 hr at room
temperature, the product was precipitated by addition of
2 volumes of ice-cold Et2O. After sedimentation and
removal of supernatant, the precipitate was dissolved in
4 N HCl/dioxane and incubated for 10 min. at room
temperature to remove the Boc protecting group. The
final product, 9-Gly-H2N-MIN, was precipitated twice
from Et2O). MS: calc. 529.54 Da, found 530.1 Da.
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Molecular Weight: 844.90

Molecular Weight: 544.56

Scheme 1. Reaction scheme for synthesis of 9-hydrazino-Ac-NH-MIN.

To PEGylate 9-Gly-NH-MIN, we added 1 equivalent of
HATU and 1.2 equivalent of iPr2EtN to 1 mL
Me2NCHO containing 100 mg of O-(N-Fmoc-2aminoethyl)-O`-(2-carboxyethyl)-undecaethyleneglycol
(PEG12 carboxylate) (Merck, Darmstadt, Germany)
stirred at room temperature for 30 min, to which 1.1
equivalent of 9-Gly-NH-MIN was added. The reaction
mixture was kept at room temperature for 2 hr under
stirring. The reaction was stopped by addition of H2O.
Taking the molecular mass (1351 Da) of 9-PEG12-GlyNH-MIN into consideration, we employed a Sephadex
G-25 column (1.7×30 cm) eluted with aqueous 0.5%
HOAc to separate the conjugate from the impurities.
The eluent corresponding to the first peak was collected,

concentrated and freeze dried. The dried sample was
redissolved in H2O, then characterized by HPLC and
MS: calc. 1351.49 Da, found 1351.6 Da. 9-PEG26-GlyNH-MIN was prepared similarly. The product was
characterized by HPLC and MS: calc. 2056.33 Da,
found 2056.0 Da.

We selected TentaGel S-NH2 polystyrene beads as a
model to investigate the release of 9-hydrazino-Ac-NHMIN from a polymeric surface. The amino groups on
O
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ii) H2NPr(OEt)2

25

Measurements of MIC for each of the MIN derivatives
without PEG (Table 1) showed that 9-Gly-NH-MIN and
9-hydrazino-Ac-NH-MIN retained significant biological
activity, compared with unmodified MIN. However, the
MIC of the two 9-PEG-MIN derivatives was
dramatically elevated. The bulky PEG modification
might have inhibited bacterial uptake of the MIN
derivatives, and/or the binding of MIN to the 30S
ribosomal subunits, resulting in the loss of bioactivity
by the PEG-MIN derivatives. This result argues against
permanent PEG tethering of MIN derivatives to medical
implants.
Table 1. MIC of MIN derivatives with S. aureus
Compound
MIC
MIC
(found)
(published)
µg/mL
µg/mL
MIN
0.125
0.125
9-H2N-MIN
2
1
2
0.5-1
9-Gly-NH-MIN
2
NA
9-hydrazino-Ac-NH-MIN
500
NA
9-PEG12-Gly-NH-MIN
1000
NA
9-PEG26-Gly-NH-MIN
S. aureus subspecies aureus Rosenbach (ATCC 25923)
were incubated in Mueller-Hinton broth at 37°C for 14
hr, noting the dilution midway between fully inhibited
25
and uninhibited bacterial proliferation
Because of the loss of bioactivity of MIN after
conjugation with PEG, we selected the acid-liable
hydrazone bond to link 9-hydrazino-Ac-NH-MIN to
solid surfaces, so that the drug could be released on
demand upon acidification of the microenvironment by
26
proliferating bacteria .
Hydrazone bonds have been widely investigated for
27
targeting drug delivery . The bond is relatively stable in
physiological pH. When the delivered drug was
absorbed through endocytosis pathway, the hydrazone
could be broken in response to the low pH in
28
cytoplasmic endosomes . To enable release on demand,
the hydrazone bonds should remain largely intact for an
effective number of days after implant insertion. For the
attachment of antibiotics to the surface of implants by
acid-labile linkers, we expect that the antibiotics should
remain stably attached on the surface for weeks to
months. Due to the reversible property of hydrazone
bonds in aqueous solution, the antibiotics attached to
implant surfaces could be released gradually at neutral
pH, but rapidly at acid pH induced by infection.

NH2
TentaGel S-NH2 resin

OCH2CH3
NHCOCH2CH2CONHCH2CH2CH
OCH2CH3
CF3CO2H/CH2Cl2
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Scheme 2. Reaction scheme for synthesis of PS-Succ-NHPr-hydrazone-9Ac-NH-MIN.

500 mg of TentaGel S-NH2 (Fluka 86364, 0.26 mmol/g)
resin were transformed to carboxylates by reaction with
1.5 equivalent of succinic anhydride in the presence of
0.1 equivalent of N,N-dimethylaminopyridine (DMAP)
catalyst dissolved in in 4 mL of pyridine (Scheme 2).
The reaction mixture was kept at 50˚C with shaking for
3 hr. A ninhydrin test showed no free amino groups
available on the surface of the resin beads. The
carboxylates on the resin were activated by HATU and
iPr2EtN at room temperature for 30 min, then coupled
with H2NPr(OEt)2 at room temperature for 3 hr. The
resin was washed with Me2NCHO and CH2Cl2, then
dried under vacuum. Next, the resin was treated with
50% CF3CO2H in CH2Cl2 for 30 min to yield aldehydemodified resin, which was washed with Me2NCHO and
CH2Cl2, then dried under vacuum overnight. 9Hydrazino-Ac-NH-MIN at 0.1 M in CHCl3 was then
reacted with the aldehyde termini to yield the acid-labile
hydrazone-linked 9-Ac-NH-MIN polystyrene beads.
The resin was washed with physiological buffer (0.15 M
NaCl, 0.01 M Na2HPO4, pH 7.4, PBS), Me2NCHO and
CH2Cl2, then dried under vacuum overnight. PS-SuccNHPr-hydrazone-9-Ac-NH-MIN resin beads were
stripped with 10% HOAc in CH2Cl2 to determine the
total loading of 9-hydrazino-Ac-NH-MIN, 52 µg/g
29
resin, by absorbance at 350 nm .
The stability of the hydrazone bond was investigated by
incubating 5.6 mg aliquots of PS-Succ-NHPrhydrazone-9-Ac-NH-MIN resin beads at 37°C under
physiological conditions in 1.5 mL of 0.1 M Na2HPO4,
pH 7.4, and under conditions of anaerobic bacterial
metabolism in a confined microenvironment in 0.1 M
NaOAc, pH 5.0. The concentration of the released 9hydrazino-Ac-NH-MIN in the buffers was determined
by absorbance at 350 nm29 (Fig. 1).
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Figure. 1. Release of 9-hydrazino-Ac-NH-MIN from PS-Succ-NHPrhydrazone-9-Ac-NH-MIN resin beads as a function of pH. Solid line: 0.1
M Na2HPO4, pH 7.4. Dashed line: 0.1 M NaOAc, pH 5.0.

The time course of 9-hydrazino-Ac-NH-MIN release
from the beads showed much faster release at pH 5.0
than at pH 7.4. After 24 hr at pH 5.0, released MIN
reached 36.7 µg/mL, or 54% of the MIN loading
measured after coupling (Fig. 1). That value is 18 times
greater than the MIC of 2 µg/mL. After 24 hr at pH 7.4,
released MIN reached 18.8 µg/mL, or 27.6% of the
MIN loading measured after coupling The leveling of
the A350 trace after 24 hr is probably the result of the
instability of hydrazino-MIN. Hence, the hydrazone
bond is not stable enough to keep 9-hydrazino-Ac-NHMIN on the surface for an extended period of time.
We also attached 9-hydrazino-Ac-NH-MIN to the
surface of Ti6Al4V foil. We prepared H2NPrSi-OTi6Al4V alloy foil as described previously for Ti6Al4V
pins17. The amine was then coupled with 4 equivalents
of glyoxylyl-8-amino-3,5-dioxaoctanoic acid in the
presence of HATU/iPr2EtN in Me2NCHO. 9Hydrazino-Ac-NH-MIN at 0.1 M in CHCl3 was coupled
to the surface of the aldehyde-PEG-NHPrSi-O-Ti6Al4V
foil for 4 hr to yield Ti-O-SiPrNH-PEG-hydrazone-9Ac-NH-MIN. The foil was washed with CH2Cl2,
Me2NCHO and double deionized H2O, then dried under
vacuum overnight. On the surface of a one cm2
Ti6Al4V foil with a maximum monolayer loading of
200 pmol30, as we found for VAN18, the amount of
strippable MIN would be too low to measure by UV
absorbance.
To determine bacterial viability on Ti6Al4V foil
substrates, control Ti6Al4V alloy foils and Ti-OSiPrNH-PEG-hydrazone-9-Ac-NH-MIN alloy foils
were sterilized by incubation with 70% EtOH, and
washed five times with autoclaved PBS. S. aureus
subspecies aureus Rosenbach were cultured in MuellerHinton broth at 250 rpm, 37°C for 14 hr. Using a 0.5
4
McFarland standard, the bacteria were diluted to 1×10
cfu/mL in Mueller-Hinton broth. The sterilized

Ti6Al4V foils were cultured with the S. aureus at 37°C
for 24 hr, after which the pH was still 7.3-7.4. For
Ti6Al4V foil, we immersed the MIN-bonded foil in the
minimum volume of 200 µL of broth. The foils were
washed three times with PBS to remove loosely
adherent bacteria, and assessed for bacterial adhesion
and viability by staining with the Live/Dead®
BacLight™ viability kit, which fluorescently labels
viable bacteria green and dead bacteria red. After
labeling, the Ti6Al4V alloy foils were washed three
times with PBS to remove nonspecific stain and
visualized by confocal laser fluorescence microscope on
a Fluoview 300 (Olympus, Melville, NY). Challenge by
S. aureus, however, showed live bacteria on all foil
samples. At physiological pH, the concentration of 9hydrazino-Ac-NH-MIN that could be released into the
medium was insufficient to inhibit the growth of S.
aureus. Even if all the attached monolayer of MIN were
released into the broth, the resulting MIN concentration
of 1.2 µg/mL would have been below the MIC of 2
µg/mL. The flat foil has much less surface area than the
porous resin beads.
For the construction of medical implants with
covalently bound broad-spectrum antibiotics for selfprotection against Gram-negative colonization, we
designed and synthesized three MIN derivatives.
Conjugation of long hydrophilic PEG spacers with MIN
at the C9 position resulted in dramatic loss of
bioactivity, which argued against the utility of
permanent linkage of MIN to the surface of medical
implants by PEG spacers.
Knowing that 9-hydrazino-Ac-NH-MIN showed
reasonable antibiotic activity, we attached it to the
surfaces of polystyrene beads and Ti6Al4V foils by an
acid-labile hydrazone bond that would permit release of
free 9-hydrazino-Ac-NH-MIN to enter bacteria,
triggered by bacterial acidification of the implant
microenvironment. The release kinetics showed a clear
difference between the rates of 9-hydrazino-Ac-NHMIN released at pH 7.4 and pH 5.0. However, the
hydrazone bond may not be stable enough for long term
medical implant application. We are also considering
methylmaleimide31 linkers to enable this strategy.
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